Detailed information for compound 287267

Basic information

Technical information
  • TDR Targets ID: 287267
  • Name: benzyl N-[(2S)-1-[(2S)-2-[[(3S)-6-(benzylamin o)-5,5-difluoro-2-methyl-4,6-dioxohexan-3-yl] carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobuta n-2-yl]carbamate
  • MW: 614.68 | Formula: C32H40F2N4O6
  • H donors: 3 H acceptors: 5 LogP: 5 Rotable bonds: 18
    Rule of 5 violations (Lipinski): 2
  • SMILES: O=C(N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)C(C(=O)NCc1ccccc1)(F)F)C(C)C)C(C)C)OCc1ccccc1
  • InChi: 1S/C32H40F2N4O6/c1-20(2)25(27(39)32(33,34)30(42)35-18-22-12-7-5-8-13-22)36-28(40)24-16-11-17-38(24)29(41)26(21(3)4)37-31(43)44-19-23-14-9-6-10-15-23/h5-10,12-15,20-21,24-26H,11,16-19H2,1-4H3,(H,35,42)(H,36,40)(H,37,43)/t24-,25-,26-/m0/s1
  • InChiKey: PHUAMFFLDHJTGD-GSDHBNRESA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • benzyl N-[(1S)-1-[(2S)-2-[[(1S)-4-(benzylamino)-3,3-difluoro-1-isopropyl-2,4-dioxo-butyl]carbamoyl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate
  • N-[(1S)-1-[[(2S)-2-[[[(1S)-4-(benzylamino)-3,3-difluoro-1-isopropyl-2,4-dioxobutyl]amino]-oxomethyl]-1-pyrrolidinyl]-oxomethyl]-2-methylpropyl]carbamic acid benzyl ester
  • phenylmethyl N-[(2S)-1-[(2S)-2-[[(3S)-5,5-difluoro-2-methyl-4,6-dioxo-6-(phenylmethylamino)hexan-3-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxo-butan-2-yl]carbamate
  • N-[(1S)-1-[(2S)-2-[[(1S)-4-(benzylamino)-3,3-difluoro-1-isopropyl-2,4-diketo-butyl]carbamoyl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamic acid benzyl ester
  • phenylmethyl N-[(2S)-1-[(2S)-2-[[(3S)-5,5-difluoro-2-methyl-4,6-dioxo-6-(phenylmethylamino)hexan-3-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
  • phenylmethyl N-[(1S)-1-[(2S)-2-[[(1S)-3,3-difluoro-1-isopropyl-2,4-dioxo-4-(phenylmethylamino)butyl]carbamoyl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate
  • N-[(1S)-1-[[(2S)-2-[[[(1S)-3,3-difluoro-1-isopropyl-2,4-dioxo-4-(phenylmethylamino)butyl]amino]-oxomethyl]-1-pyrrolidinyl]-oxomethyl]-2-methylpropyl]carbamic acid phenylmethyl ester

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens elastase, neutrophil expressed Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus transmembrane protease serine 3 elastase, neutrophil expressed 267 aa 236 aa 27.5 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Plasmodium falciparum thioredoxin reductase 0.0049 0.0067 0.5
Mycobacterium tuberculosis Probable reductase 0.0112 0.1682 0.8342
Mycobacterium ulcerans glutamine-binding lipoprotein GlnH 0.0079 0.0829 0.5
Echinococcus multilocularis Glutamate receptor, ionotropic kainate 3 0.011 0.1618 0.1618
Mycobacterium tuberculosis Probable glutamine-binding lipoprotein GlnH (GLNBP) 0.0079 0.0829 0.3939
Mycobacterium tuberculosis Probable dehydrogenase 0.0112 0.1682 0.8342
Treponema pallidum amino acid ABC transporter, periplasmic binding protein 0.0079 0.0829 0.5
Trypanosoma brucei trypanothione reductase 0.0049 0.0067 0.5
Plasmodium vivax glutathione reductase, putative 0.0049 0.0067 0.5
Mycobacterium tuberculosis Probable membrane NADH dehydrogenase NdhA 0.0112 0.1682 0.8342
Trypanosoma cruzi trypanothione reductase, putative 0.0049 0.0067 0.5
Echinococcus granulosus thioredoxin glutathione reductase 0.0049 0.0067 0.0067
Brugia malayi Thioredoxin reductase 0.0049 0.0067 0.5
Mycobacterium tuberculosis Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras 0.0125 0.2002 1
Leishmania major trypanothione reductase 0.0049 0.0067 0.5
Plasmodium falciparum glutathione reductase 0.0049 0.0067 0.5
Echinococcus granulosus glutamate receptor NMDA 0.0327 0.7188 0.7188
Mycobacterium tuberculosis Probable NADH dehydrogenase Ndh 0.0112 0.1682 0.8342
Brugia malayi glutathione reductase 0.0049 0.0067 0.5
Chlamydia trachomatis glutamine binding protein 0.0079 0.0829 0.5
Loa Loa (eye worm) glutathione reductase 0.0049 0.0067 0.5
Plasmodium vivax thioredoxin reductase, putative 0.0049 0.0067 0.5
Echinococcus multilocularis nmda type glutamate receptor 0.0436 1 1
Mycobacterium tuberculosis Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB 0.0112 0.1682 0.8342
Toxoplasma gondii thioredoxin reductase 0.0049 0.0067 0.5
Schistosoma mansoni glutamate receptor NMDA 0.0373 0.8382 1
Mycobacterium tuberculosis NAD(P)H quinone reductase LpdA 0.0125 0.2002 1
Echinococcus multilocularis thioredoxin glutathione reductase 0.0049 0.0067 0.0067
Treponema pallidum amino acid ABC transporter, periplasmic binding protein (hisJ) 0.0079 0.0829 0.5
Echinococcus granulosus nmda type glutamate receptor 0.0342 0.7592 0.7592
Mycobacterium leprae DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE 0.0125 0.2002 1
Echinococcus multilocularis nmda type glutamate receptor 0.0342 0.7592 0.7592
Echinococcus multilocularis glutamate receptor NMDA 0.0327 0.7188 0.7188
Mycobacterium tuberculosis Putative ferredoxin reductase 0.0112 0.1682 0.8342
Loa Loa (eye worm) thioredoxin reductase 0.0049 0.0067 0.5
Chlamydia trachomatis arginine ABC transporter substrate-binding protein ArtJ 0.0079 0.0829 0.5
Mycobacterium tuberculosis Probable oxidoreductase 0.0125 0.2002 1

Activities

Activity type Activity value Assay description Source Reference
Ki (binding) = 0.4 nM In vitro inhibitory activity against human neutrophil elastase (HNE) catalyzed hydrolysis of the synthetic substrate MeO-Suc-Ala- Ala-Pro-Val-pN ChEMBL. 7837243
Ki (binding) = 0.4 nM In vitro inhibitory activity against human neutrophil elastase (HNE) catalyzed hydrolysis of the synthetic substrate MeO-Suc-Ala- Ala-Pro-Val-pN ChEMBL. 7837243

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.